Search

Juergen A Richt

from Manhattan, KS
Age ~65
Get Report
Also known as:
Juergen C Richt, Vergen A Richt, Jurgen Richt
Phone and address:
2647 Bent Tree Rd, Manhattan, KS 66502
(785) 537-6863
Related to:
Cheryl RichtEric Jackson, 43Jean Carlow, 84Elisabeth Richt
Connected to:
Jesce Richt, 41Ryan J Richt, 39Ashley Richtarik, 34Melissa N Richtarik, 37Peter Richtarik, 47Al W Richter, 110Alan J Richter, 77Albert Richter, 95Alison G Richterman, 66Amanda M Richter, 43

Juergen Richt Phones & Addresses

  • 2647 Bent Tree Rd, Manhattan, KS 66502 (785) 537-6863
  • Lamoni, IA
  • Philadelphia, PA
  • 1501 Reagan Dr, Ames, IA 50010 (515) 232-8372
  • Baltimore, MD
  • Deerfield Bch, FL
  • Decatur, IA
  • Westminster, SC

Resumes

Resumes

Juergen Richt Photo 1

Director Of Ceezad-Center Of Excellence For Emerging And Zoonotic Animal Diseases

View page
Location:
Washington, DC
Industry:
Research
Work:
KSU since 2010
Regents Distinguished Professor
US Department of Homeland Security since Feb 2010
Director of CEEZAD-Center of Excellence for Emerging and Zoonotic Animal Diseaaes
Kansas Bioscience Authority since Jul 2008
Eminent Scholar
Education:
Kansas State University 2008 - 2018
Doctorates, Doctor of Veterinary Medicine, Doctor of Philosophy, Philosophy, Virology The Johns Hopkins University 1989 - 1992
Justus Liebig University Giessen 1985 - 1989
Doctorates, Doctor of Philosophy, Philosophy, Virology, Immunology
Skills:
Infectious Diseases
Microbiology
Molecular Biology
Immunology
Science
Life Sciences
Virology
Lifesciences
Pcr
Research
Biotechnology
Cell Culture
Strategic Planning
Vaccines
Epidemiology
Genomics
Biochemistry
Genetics
Veterinary
Western Blotting
Elisa
Technology Transfer
Project Management
Cell Biology
Animal Models
Public Speaking
Molecular Cloning
Cell
Laboratory
R&D
Rt Pcr
Dna
In Vitro
Chemistry
Data Analysis
Protein Chemistry
Veterinary Medicine
Microscopy
Biology
Protein Purification
Sequencing
Polymerase Chain Reaction
Purification
Protein Expression
Dna Extraction
Languages:
German
French
English
Spanish
Juergen Richt Photo 2

Juergen Richt

View page

Publications

Us Patents

Polymorphism In Bovine Prion Protein Gene Sequence

View page
US Patent:
7867710, Jan 11, 2011
Filed:
Apr 18, 2007
Appl. No.:
11/787784
Inventors:
Juergen A. Richt - Ames IA, US
Assignee:
The United States of America as represented by the Secretary of Agriculture - Washington DC
International Classification:
C12Q 1/68
C12P 19/34
C07H 21/02
C07H 21/04
US Classification:
435 6, 435 912, 536 231, 536 243
Abstract:
A specific, non-synonymous SNP in the Prnp gene encoding the bovine prion protein affects the susceptibility of bovine animals to bovine spongiform encephalopathy (BSE). Depending on the number of octapeptide repeat units present in the Prnp gene, the position of the SNP is either nucleotide 631 of exon 3 (codon 211) when the Prnp gene comprises six octapeptide repeat region sequences, nucleotide 607 of exon 3 (codon 203) when the Prnp gene comprises five octapeptide repeat region sequences, or nucleotide 655 of exon 3 (codon 219) when the Prnp gene comprises seven octapeptide repeat region sequences. Alleles of the bovine Prnp wherein the SNP at these positions is lysine (K) at the corresponding amino acids (i. e. , 211, 203 or 219) in the bovine prion protein are all indicative of increased susceptibility to BSE in comparison to alleles which encode glutamic acid (E) at the same position. This SNP may be used as a marker for selecting bovines susceptible to BSE for disposal and/or removal from breeding, the human food and animal feed supplies.

H2N3 Influenza A Viruses And Methods Of Use

View page
US Patent:
8084594, Dec 27, 2011
Filed:
Jul 11, 2008
Appl. No.:
12/171992
Inventors:
Marie Rene Gramer - Shoreview MN, US
Kelly Lager - Colo IA, US
Wenjun Ma - Ames IA, US
Juergen Richt - Manhattan KS, US
Amy Vincent - Nevada IA, US
Assignee:
The United States of America as represented by the Secretary of Agriculture - Washington DC
Iowa State University Research Foundation, Inc. - Ames IA
Regents of the University of Minnesota - St. Paul MN
International Classification:
C07H 21/02
C12N 15/00
US Classification:
536 231, 4353201
Abstract:
The present invention provides influenza A viruses that include a hemagglutinin subtype H2, a neuraminidase subtype N3, or the combination thereof. Included in the present invention are H2 hemagglutinins and N3 neuraminidases, and the polynucleotides encoding the polypeptides. Antibody to the polypeptides, and methods of using the viruses, polypeptides, polynucleotides, and antibodies are also provided.

Genetically Engineered Swine Influenza Virus And Uses Thereof

View page
US Patent:
8124101, Feb 28, 2012
Filed:
Jun 1, 2005
Appl. No.:
11/628292
Inventors:
Peter Palese - Leonia NJ, US
Adolfo Garcia-Sastre - New York NY, US
Richard J. Webby - Memphis TN, US
Juergen A. Richt - Ames IA, US
Robert G. Webster - Memphis TN, US
Kelly M. Lager - Colo IA, US
Assignee:
Mount Sinai School of Medicine - New York NY
St. Jude Children's Research Hospital - Memphis TN
The United States of America as represented by The Secretary of Agriculture - Washington DC
International Classification:
A61K 39/145
A61K 49/00
US Classification:
4242061, 4242091, 424 92
Abstract:
The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

Polymorphism In Bovine Prion Protein Gene Sequence

View page
US Patent:
8617812, Dec 31, 2013
Filed:
Dec 16, 2010
Appl. No.:
12/969744
Inventors:
Juergen A. Richt - Manhattan KS, US
Assignee:
The United States of America, as represented by the Secretary of Agriculture - Washington DC
International Classification:
C12Q 1/68
C12P 19/34
C07H 21/04
US Classification:
435 61, 435 912, 435 71, 536 231
Abstract:
A specific, non-synonymous SNP in the Prnp gene encoding the bovine prion protein affects the susceptibility of bovine animals to bovine spongiform encephalopathy (BSE). Depending on the number of octapeptide repeat units present in the Prnp gene, the position of the SNP is either nucleotide 631 of exon 3 (codon 211) when the Prnp gene comprises six octapeptide repeat region sequences, nucleotide 607 of exon 3 (codon 203) when the Prnp gene comprises five octapeptide repeat region sequences, or nucleotide 655 of exon 3 (codon 219) when the Prnp gene comprises seven octapeptide repeat region sequences. Alleles of the bovine Prnp wherein the SNP at these positions is lysine (K) at the corresponding amino acids (i. e. , 211, 203 or 219) in the bovine prion protein are all indicative of increased susceptibility to BSE in comparison to alleles which encode glutamic acid (E) at the same position. This SNP may be used as a marker for selecting bovines susceptible to BSE for disposal and/or removal from breeding, the human food and animal feed supplies.

Genetically Engineered Swine Influenza Virus And Uses Thereof

View page
US Patent:
20130034581, Feb 7, 2013
Filed:
Nov 23, 2011
Appl. No.:
13/304175
Inventors:
Peter Palese - Leonia NJ, US
Adolfo Garcia-Sastre - New York NY, US
Richard J. Webby - Memphis TN, US
Juergen A. Richt - Ames IA, US
Robert G. Webster - Memphis TN, US
Kelly M. Lager - Colo IA, US
International Classification:
C12N 7/04
C12N 5/073
A61K 39/12
C12N 5/07
US Classification:
4241991, 435236, 435350, 435349
Abstract:
The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

Genetically Engineered Swine Influenza Virus And Uses Thereof

View page
US Patent:
20180369363, Dec 27, 2018
Filed:
Sep 10, 2018
Appl. No.:
16/126791
Inventors:
- New York NY, US
- Memphis TN, US
- Washington WA, US
Juergen A. Richt - Ames IA, US
Robert G. Webster - Memphis TN, US
Kelly M. Lager - Colo IA, US
Assignee:
Icahn School of Medicine at Mount Sinai - New York NY
St. Jude Children's Research Hospital - Memphis TN
The United States of America, As Represented by the Secretary of Agriculture - Washington WA
International Classification:
A61K 39/145
C12N 7/00
A61K 39/12
A61K 39/00
Abstract:
The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

Genetically Engineered Swine Influenza Virus And Uses Thereof

View page
US Patent:
20170151324, Jun 1, 2017
Filed:
Dec 12, 2016
Appl. No.:
15/375664
Inventors:
- New York NY, US
- Memphis TN, US
- Washington DC, US
Juergen A. Richt - Ames IA, US
Robert G. Webster - Memphis TN, US
Kelly M. Lager - Colo IA, US
Assignee:
Icahn School of Medicine at Mount Sinai - New York NY
St. Jude Children's Research Hospital - Memphis TN
The United States of America, As Represented by the Secretary of Agriculture - Washington DC
International Classification:
A61K 39/145
C12N 7/00
Abstract:
The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

Genetically Engineered Swine Influenza Virus And Uses Thereof

View page
US Patent:
20150273049, Oct 1, 2015
Filed:
Mar 3, 2015
Appl. No.:
14/636651
Inventors:
- New York NY, US
- Memphis TN, US
- Washington DC, US
Juergen A. Richt - Ames IA, US
Robert G. Webster - Memphis TN, US
Kelly M. Lager - Colo IA, US
Assignee:
Icahn School of Medicine at Mount Sinai - New York NY
St. Jude Children's Research Hospital - Memphis TN
The United States of America, As Represented by the Secretary of Agriculture - Washington DC
International Classification:
A61K 39/145
C12N 7/00
Abstract:
The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
Control profile
Juergen A Richt from Manhattan, KS, age ~65 Get Report